Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M

Rapamycin Prevents the Development and Progression of Mutant Epidermal Growth Factor Receptor Lung Tumors with the Acquired Resistance Mutation T790M

Lung cancer in never-smokers is an important disease often characterized by mutations in epidermal growth factor receptor (EGFR), yet risk reduction measures and effective chemopreventive strategies have not been established. We identify mammalian target of rapamycin (mTOR) as potentially valuable t...

Full description

Bibliographic Details
Main Authors: Shigeru Kawabata, José R. Mercado-Matos, M. Christine Hollander, Danielle Donahue, Willie Wilson III, Lucia Regales, Mohit Butaney, William Pao, Kwok-Kin Wong, Pasi A. Jänne, Phillip A. Dennis
Format: Article
Language:English
Published: Elsevier 2014-06-01
Series:Cell Reports
Online Access:http://www.sciencedirect.com/science/article/pii/S2211124714004331

Internet

http://www.sciencedirect.com/science/article/pii/S2211124714004331

Similar Items